HONOLULU (HawaiiNewsNow) - Manoa-based Cardax Pharmaceuticals is developing synthetic astaxanthin, chemically identical to the astaxanthin produced by Cyanotech, Mera Pharmaceuticals and other companies. CEO David Watumull and partner BASF, a German chemical company, are betting that demand for astaxanthin will exceed the capacity of natural producers. Astaxanthin is marketed mostly as an antioxidant, but it's also anti-inflammatory without the side effects of many other anti-inflammatory drugs. Watumull spoke with Howard this morning
Copyright 2015. Hawaii News Now. All Rights Reserved.